Table 3 Immunohistochemistry staining of subungual benign melanocytic proliferation and subungual melanoma in situ
Subungual benign melanocytic proliferation (n = 14), n (%) | Subungual Melanoma in situ (n = 13), n (%) | |
|---|---|---|
cyclin D1 nuclear immunostaining | ||
0% | 2 (14.3) | 2 (15.4) |
> 0–10% | 0 (0.0) | 2 (15.4) |
> 10–20% | 2 (14.3) | 4 (30.8) |
> 20–30% | 0 (0.0) | 0 (0.0) |
> 30–40% | 0 (0.0) | 0 (0.0) |
> 40–50% | 0 (0.0) | 0 (0.0) |
> 50–60% | 0 (0.0) | 0 (0.0) |
> 60–70% | 0 (0.0) | 1 (7.7) |
> 70–80% | 3 (21.4) | 0 (0.0) |
> 80–90% | 3 (21.4) | 1 (7.7) |
> 90–100% | 4 (28.6) | 3 (23.1) |
PRAME nuclear immunostaining | ||
0% | 13 (92.9) | 3 (23.1) |
> 0–10% | 0 (0.0) | 0 (0.0) |
> 10–20% | 1 (7.1) | 0 (0.0) |
> 20–30% | 0 (0.0) | 0 (0.0) |
> 30–40% | 0 (0.0) | 0 (0.0) |
> 40–50% | 0 (0.0) | 0 (0.0) |
> 50–60% | 0 (0.0) | 3 (23.1) |
> 60–70% | 0 (0.0) | 0 (0.0) |
> 70–80% | 0 (0.0) | 1 (7.7) |
> 80–90% | 0 (0.0) | 2 (15.4) |
> 90–100% | 0 (0.0) | 4 (30.8) |